GSC Advanced Research and Reviews
eISSN: 2582-4597 CODEN (USA): GARRC2
Cross Ref DOI: 10.30574/gscarr
Journal homepage: https://gsconlinepress.com/journals/gscarr/

(REVIEW ARTICLE)

Check for updates

Review on molecular designing of polymeric carriers use in gene therapy for diabetes

Sakshi R Shahu [1,*], Tejaswini J Taware [2], Sunil S Bhagat [3] and Swati Deshmukh [4]

[1] *Bachelor of Pharmacy, Shraddha Institute of pharmacy, Washim, Maharashtra, India.*
[2] *Bachelor of pharmacy, Shraddha Institute of pharmacy, Washim, Maharashtra, India.*
[3] *Department of Industrial pharmacy, Shraddha Institute of pharmacy, Washim, Maharashtra, India.*
[4] *Department of pharmacology, Shraddha Institute of pharmacy, Washim, Maharashtra, India.*

GSC Advanced Research and Reviews, 2024, 21(03), 316-323

Publication history: Received on 11 September 2024; revised on 11 December 2024; accepted on 13 December 2024

Article DOI: https://doi.org/10.30574/gscarr.2024.21.3.0385

Abstract

Gene therapy holds promise for treating diabetes by addressing its root causes at the molecular level. A key factor in its success is the development of effective delivery systems, with polymeric carriers emerging as versatile vehicles. This review highlights the molecular design of polymeric carriers for diabetes gene therapy, focusing on critical parameters like polymer structure, size, charge, and surface modification that influence gene encapsulation and release.

Biodegradable polymers such as PLGA, chitosan, and PEI are emphasized for their ability to protect therapeutic genes and enable controlled release. In diabetes, these carriers aim to deliver genes that modulate insulin production, enhance β-cell regeneration, or prevent immune-mediated destruction. The review also explores stimulus-responsive polymers that offer on-demand release based on glucose levels.

Recent preclinical and clinical studies are discussed, addressing challenges and strategies for optimizing polymeric carriers. These molecular design insights could pave the way for safer, more efficient gene delivery systems in diabetes treatment.

This abstract emphasizes the design principles, challenges, and emerging strategies in polymeric carrier systems for gene therapy in diabetes.

Keywords: Gene therapy; Role of gene therapy in diabetes; Polymeric Carriers; Recent advancement; Application; Advantages; Disadvantages

1. Introduction

Gene therapy holds immense potential for the treatment of various genetic disorders, including diabetes, by offering a means to modify or correct the underlying causes of the disease at the molecular level. Among the various approaches to gene delivery, polymeric carriers have emerged as promising vehicles due to their versatility, biocompatibility, and capacity for targeted delivery. Polymeric carriers can be engineered to protect genetic material, enhance cellular uptake, and ensure controlled release, making them suitable for delivering therapeutic genes or RNA to specific tissues.

Diabetes, a chronic metabolic disorder, results from the failure of insulin production or the body's inability to utilize insulin effectively. Current therapeutic strategies focus primarily on managing symptoms rather than addressing the root cause of the disease. Gene therapy presents an innovative solution by targeting specific genetic mechanisms involved in insulin production, glucose regulation, and β-cell survival. However, one of the major challenges in the application of gene therapy is the development of safe and effective carriers that can navigate the physiological barriers and deliver genetic material efficiently to the pancreas or other relevant tissues.

* Corresponding author: Sakshi R Shahu

Polymeric carriers, with their tunable chemical structures and diverse functional groups, offer a platform for optimizing gene delivery systems tailored to the unique needs of diabetic patients. These materials can be designed to improve the stability of genetic material, avoid immune system activation, and enable targeted release in response to specific biological stimuli. Moreover, advances in molecular design and polymer chemistry have allowed the development of stimuli-responsive and degradable polymers, further enhancing the precision and safety of gene delivery systems.



Figure 1 Sign of Diabetes

Diabetes mellitus, particularly type 1 and type 2, affects millions of people worldwide. While conventional treatments primarily focus on regulating blood glucose levels, they do not address the underlying genetic causes of diabetes. Gene therapy has emerged as a promising alternative to conventional therapies, aiming to restore or replace defective genes responsible for the disease's onset. One of the critical challenges in gene therapy is delivering genetic material efficiently and safely to the target cells. In this context, polymeric carriers have garnered significant attention for their role as vectors in delivering genes, due to their versatility, biocompatibility, and ability to be designed at the molecular level to achieve the desired therapeutic outcomes.

This review paper will explore the molecular design of polymeric carriers used in gene therapy for diabetes, highlighting recent advancements in polymer chemistry, the design criteria for effective carriers, and the challenges that remain in translating these systems into clinical applications.

2. Role of Gene Therapy in Diabetes

Gene therapy aims to modulate or repair the defective genes responsible for insulin production or the body's ability to use insulin effectively. For instance, introducing genes that encode insulin or promoting the regeneration of insulin-

producing beta cells in the pancreas can offer long-term solutions for diabetes management. To successfully deliver these therapeutic genes, the vectors used must protect the genetic material, enable its entry into the target cells, and release it in a functional form.



Figure 2 Gene therapy

3. Challenges in Gene Delivery

The successful application of gene therapy in diabetes treatment requires overcoming several barriers:

- **Stability of genetic material:** DNA or RNA used in therapy must be protected from degradation.
- **Targeted delivery:** Genetic material should reach the specific tissues or cells (such as pancreatic beta cells).
- **Efficient cellular uptake:** Carriers need to ensure the therapeutic genes are taken up by cells.
- **Biocompatibility:** Materials used in the vectors should be non-toxic and should not elicit an immune response.

4. Polymeric Carriers in Gene Therapy

Polymeric carriers have been explored as non-viral vectors for gene delivery due to their customizable properties, lower immunogenicity compared to viral vectors, and ease of production. These carriers can be designed at the molecular level to optimize their efficiency for specific therapeutic applications, making them suitable for diabetes gene therapy.



Figure 3 Classification of Polymer

There are different types of polymers use in gene therapy,

5. Key types of polymeric carriers include

- **Polyethylenimine (PEI):** One of the most widely used polymers for gene delivery. PEI has a high density of amine groups, allowing it to bind with genetic material (like DNA) and form complexes that facilitate cellular uptake. PEI's capacity to disrupt endosomal membranes also aids in the release of genetic material into the cell's cytoplasm. However, PEI can be cytotoxic at higher molecular weights, necessitating careful design to balance efficiency with safety.
- **Poly(lactic-co-glycolic acid) (PLGA):** PLGA is a biodegradable polymer that can encapsulate genetic material within nanoparticles. These nanoparticles can protect DNA from degradation and allow controlled release over time. PLGA's biodegradability and biocompatibility make it a promising candidate for sustained gene delivery in diabetes therapy.
- **Chitosan:** A natural polymer with mucoadhesive properties, chitosan has been used in nanoparticle formulations for gene delivery. It is non-toxic, biodegradable, and has been shown to enhance the stability of genetic material in biological environments. Chitosan's positive charge enables it to bind with negatively charged DNA, facilitating gene transport into cells.
- **Dendrimers:** Dendrimers are highly branched, tree-like polymers that can be engineered with multiple surface functional groups. These structures allow for a high degree of control over the size and surface characteristics of the carriers. In gene delivery, dendrimers can be used to encapsulate genetic material and facilitate cellular entry while minimizing toxicity.

6. Molecular Design Strategies for Polymeric Carriers

Molecular design plays a pivotal role in enhancing the efficacy of polymeric carriers. Key strategies include:

- **Surface Modification:** The surface of polymeric carriers can be modified with ligands or antibodies that target specific cell receptors. For diabetes, targeting insulin-producing beta cells in the pancreas is crucial. Surface modifications can improve the specificity of gene delivery, reducing off-target effects.
- **Size and Charge Optimization:** The size of polymeric carriers influences their ability to penetrate tissues and be taken up by cells. Smaller nanoparticles can travel more easily through biological barriers, but must be large enough to protect the genetic material. Similarly, optimizing the charge of the carrier affects how well it can bind with genetic material and interact with cellular membranes.
- **Stimuli-Responsive Polymers:** Polymers that respond to changes in pH, temperature, or other environmental stimuli can provide controlled release of genetic material. For instance, nanoparticles that degrade in response to the slightly acidic environment inside endosomes can ensure that the genetic material is released into the cell cytoplasm, enhancing the efficiency of gene delivery.

- **Biodegradability and Safety:** Designing polymers that degrade into non-toxic by products is essential for reducing the risk of toxicity and long-term accumulation in tissues. The rate of degradation can also be controlled to allow for sustained release of therapeutic genes over time.

7. Recent advancement of polymer chemistry

Recent advancements in the molecular design of polymeric carriers for gene therapy, particularly for the treatment of diabetes, focus on improving delivery efficiency, biocompatibility, and targeted delivery to specific cells or tissues. Key developments in this area include:

- **Polycationic Carriers for Enhanced Gene Delivery:** Polymeric carriers designed with polycationic materials, such as polyethylenimine (PEI), have shown great potential in gene therapy. These materials form complexes with negatively charged DNA or RNA, facilitating their cellular uptake. To minimize toxicity while retaining gene transfection efficiency, researchers are modifying PEI-based polymers by incorporating biodegradable linkages or adding biocompatible polymers like poly(ethylene glycol) (PEG).
- **Nanoparticles for Controlled Release:** Polymeric nanoparticles, particularly those made from biodegradable polymers like polylactic-co-glycolic acid (PLGA) and chitosan, are being extensively researched for controlled and sustained gene release. These nanoparticles protect genetic material from degradation, allowing for efficient delivery to pancreatic cells for diabetes treatment. Recent advancements include surface modifications to enhance targeting specificity to beta cells.
- **pH-sensitive and Responsive Carriers:** Another breakthrough is the development of pH-sensitive polymers that release therapeutic genes in response to the acidic environments of certain tissues or intracellular compartments. This helps in the precise delivery of genetic material to specific tissues, reducing off-target effects. These smart carriers are being optimized for targeted delivery to pancreatic cells in diabetic patients.
- **Polymers for mRNA Delivery:** With the success of mRNA-based therapies, research in polymer chemistry has expanded to create carriers optimized for mRNA delivery. Polymers like lipid nanoparticles (LNPs) are now being explored for delivering mRNA that encodes for insulin or other diabetes-related proteins. These carriers are designed to enhance cellular uptake, protect mRNA from degradation, and ensure efficient translation inside target cells.

These advancements are helping to overcome major challenges in gene therapy for diabetes, such as the stability of genetic materials and targeting efficiency, making polymeric carriers a promising tool for future diabetes treatments.

8. Applications in Diabetes

In diabetes gene therapy, polymeric carriers can be used to deliver genes that:

- **Restore insulin production:** Delivering genes that encode insulin to the pancreas, or to alternative sites like the liver, can help the body produce its own insulin.
- **Promote beta-cell regeneration:** By delivering growth factors or genes that stimulate beta-cell proliferation, it may be possible to regenerate the insulin-producing cells lost in type 1 diabetes.
- **Modulate immune responses:** Gene therapy can also be used to modulate the immune system, preventing the autoimmune destruction of beta cells in type 1 diabetes.

9. Usages of molecular designing of polymeric carriers in gene therapy for diabetes:

The use of molecularly designed polymeric carriers in gene therapy for diabetes holds significant potential to address the underlying causes of the disease by delivering therapeutic genes directly to target cells, such as pancreatic β-cells, or modulating insulin production.

- Gene Delivery for Insulin Production
- Gene Editing for Autoimmune Modulation
- Enhancing Insulin Sensitivity in Type 2 Diabetes
- Enhancement of Antioxidant or Anti-Inflammatory Genes
- Regenerating Pancreatic β-Cells
- Delivery of RNA Therapeutics
- Controlled and Targeted Gene Release
- Dual or Co-Delivery of Therapeutics

- Non-Viral Alternative to Traditional Vectors
- Challenges in Treating Diabetes Complications

10. Risk factors

Incorporating molecularly designed polymeric carriers for gene therapy in diabetes poses several risk factors, which should be carefully considered. These risks can affect both the safety and efficacy of the treatment. Here are key risk factors you can include in your review paper:

- Toxicity and Biocompatibility
- Immune Response and Inflammation
- Unpredictable Degradation and Clearance
- Off-Target Effects
- Endosomal Escape and Intracellular Delivery Failure
- Uncontrolled Gene Expression
- Risk of Mutagenesis
- Short Circulation Time
- Aggregation and Thrombosis Risk
- Patient-Specific Variability
- Risk of Chronic Inflammation
- Complex Regulatory Approval Process
- Ethical and Public Acceptance Issues
- Difficulty in Treating Complications of Diabetes

Advantages

Molecular designing of polymeric carriers offers several advantages in gene therapy for diabetes.

- Targeted Delivery
- Enhanced Biocompatibility and Biodegradability
- Controlled Release
- Protection of Genetic Material
- Customizable Functional Groups
- Reduced Immune Response
- Potential for Co-Delivery of Therapeutic Agents
- Versatility in Gene Editing Technologies
- Scalability and Cost-Effectiveness
- Adaptability to Different Delivery Routes
- Minimal Genetic Mutagenesis
- Overcoming Delivery Barriers

Disadvantages:

Molecular design of polymeric carriers for gene therapy in treating diabetes holds great potential, but there are several disadvantages and challenges that must be considered. These challenges relate to the complexities of both the disease and the technologies involved in gene therapy. Here are some key disadvantages:

- Customization Requirement
- Polydispersity Issues
- Immune Response
- Toxic Byproducts
- Cell and Tissue Specificity
- Difficulties in Crossing Biological Barriers
- Protection of Gene Material
- Release Kinetics
- Cost and Time Factors
- Long-Term Effects Unknown
- Risk of Tumorigenesis

- Influence of Hyperglycemia and Immune Complications
- Patient-Specific Variability

11. Conclusion

The molecular design of polymeric carriers is critical to the success of gene therapy for diabetes. By tailoring the properties of polymers at the molecular level, researchers can enhance the efficiency, safety, and specificity of gene delivery. As advancements continue in the development of biodegradable, biocompatible, and targeted polymeric carriers, gene therapy holds the potential to transform the treatment landscape for diabetes, offering long-term solutions that address the root causes of the disease rather than merely managing its symptoms.

Future Perspectives

Future research will likely focus on further optimizing polymeric carrier designs, including the development of multifunctional polymers that combine targeting, controlled release, and immune modulation capabilities. With continued advancements, polymeric carriers could play a crucial role in making gene therapy a viable, mainstream treatment option for diabetes and other genetic disorders.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Han CK, Sa YM, Kim SW. Polymeric gene carriers. Crit Rev Eukaryot Gene Expr. 2005;15(4):331-60.

[2] Khan M, Zhao J, Gao B, Feng Y. Polymeric nano-carriers for on-demand delivery of genes via specific responses to stimuli. J Control Release. 2021;332:304-21.

[3] Park TG, Jeong JH, Kim SW. Current status of polymeric gene delivery systems. Adv Drug Deliv Rev. 2006;58(4):467-86.

[4] Thomas TJ, Tajmir-Riahi HA, Pillai CKS. Biodegradable polymers for gene delivery. Trends Biotechnol. 2010;28(3):142-50.

[5] Jogdeo CM, Era S. Beyond lipids: Exploring advances in polymeric gene delivery in lipid nanoparticles. Adv Mater. 2024;36(30):170-80.

[6] Mirmira RG, Nakayama M, Georgia S. Gene therapy for diabetes: Targeting insulin production and β-cell regeneration. Gene Ther. 2014;10(5):243-52.

[7] Mintzer MA, Simanek EE. Polymeric carriers in gene therapy for diabetes. Chem Rev. 2009;109(6):259-302.

[8] Lynn DM, Langer R. Non-viral vectors for gene therapy: Polymeric systems. Adv Drug Deliv Rev. 2000;17(1):703-7.

[9] Zhang Y, Satterlee A, Huang L. Recent advances in polymeric carriers for gene delivery. Curr Opin Chem Biol. 2014; 28:7-14.

[10] Li S, Huang L. Biocompatible and biodegradable polymer-based vectors for gene therapy. Adv Drug Deliv Rev. 2006; 114:1-11.

[11] Rui Y, Wilson DR, Green JJ. Engineering polymeric carriers for targeted gene therapy in diabetes. Adv Drug Deliv Rev. 2016; 107:354-71.

[12] Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol. 2000;18(1):33-7.

[13] Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3(3):1377-97.

[14] Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev. 2010;62(1):12-27.

[15] Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethyleneimine. Proc Natl Acad Sci U S A. 1995;92(16):7297-301.

[16] Fodor AA, McKnight AJ. Gene therapy for diabetes: Looking to the future. Diabetes Ther. 2020;11(3):567-81.

[17] Zhang J, Misra RDK. Magnetic drug-targeting carrier encapsulated with thermosensitive smart polymer: Core-shell nanoparticle carrier and drug release response. Acta Biomater. 2007;3(6):838-50.

[18] Jain S, Jain S. Advances in the development of gene therapy for diabetes. Diabetes Ther. 2017;8(4):717-33.

[19] Kang HC, Sa YM, Kim SW. Polymeric gene carriers. Crit Rev Eukaryote Gene Expr. 2005;15(4):331-60.

[20] Kang HC, Sa YM, Kim SW. Polymeric gene carriers. Crit Rev Eukaryote Gene Expr.

[21] Zhao R, Lu Z, Yang J, Zhang L, Li Y, Zhang X. Drug delivery system in the treatment of diabetes mellitus. Front Bioeng Biotechnol. 2020;8:880.

[22] Rai R, Alwani S, Ildiko. Polymeric nanoparticles in gene therapy: new avenues of design and optimization for delivery applications. Nanomaterials (Basel). 2019;11(745):1-30. Doi:10.3390/nano11030745.

[23] Han S, Mahato RI, Sung YK, Kim SW. Development of biomaterials for gene therapy. Mol Ther. 2000;2(4):302-17.

[24] Wong MS, Hawthorne WJ, Manolios N. Gene therapy in diabetes. J Transl Genet Genom. 2020;1(3):165-175.

[25] Dezashibi HM, Shabani A. A mini-review of current treatment approaches and gene therapy as potential interventions for diabetes mellitus types 1. J Diabetes Metab Disord. 2023;1-7.

[26] Akash MSH, Rehman K, Chen S. Natural and synthetic polymers as drug carriers for delivery of therapeutic proteins. Drug Dev Ind Pharm. 2015;55(3):371-406.

[27] Ghiasi MR, Mohammad H, Symonds ME, Tabei SMB, Salehi AR, Jafarpour S, et al. Efficacy of insulin-targeted gene therapy for type 1 diabetes mellitus: a systematic review and meta-analysis of rodent studies. Diabetes Metab Syndr Obes. 2020;23:406-415.

[28] Bottino R, Lemarchand P, Trucco M, Giannoukakis N. Gene- and cell-based therapeutics for type 1 diabetes mellitus. Gene Ther. 2003;10:875-878.

[29] Smail HO. The role of gene therapy in the treatments of type 1 diabetes mellitus: a review. J Diabetes Metab Disord. 2020;9(2):57-64.

[30] Tasyurek MH, Altunbas HA, Canatan H, Griffith TS, Sanlioglu S. P-1-mediated gene therapy approaches for diabetes treatment. Gene Ther Mol Biol. 2014;16:e7.

[31] D'Anneo A, Rood P, Bottino R, Balamurugan AN, He J, Giannoukakis N. Gene therapy and type 1 diabetes mellitus. Immunol Res. 2006;36(1-3):83-89.

[32] Chellappan DK, Sivam NS, Xiang TK, Pan LW, Fui TZ, Kien C, Nico K, Yi FJ, Chellian J, Cheng LL, Dahiya R, Gupta G, Singhvi G, Nammi S, Hansbro PM, Dua K. Gene therapy and type 1 diabetes mellitus. Biomed Pharmacother. 2018;105:1188-1200.

[33] Kachhawa H. Gene therapy in diabetes: a review of case studies conducted over mice to cure type 2 diabetes and obesity. Int J Res Publ Semin. 2022;13(2):Apr-Jun.

[34] Handorf AM, Sollinger HW, Alam T. Insulin gene therapy for type 1 diabetes mellitus: unique challenges require innovative solutions. In: Sollinger H, editor. Modern Tools For Genetic Engineering. 2016. P. 134-161